Get the Stockscreener App
6.925
0.79%
-0.055
Aldeyra Therapeutics Inc stock is traded at $6.925, with a volume of 246.16K.
It is down -0.79% in the last 24 hours and up +7.03% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$6.98
Open:
$6.9
24h Volume:
246.16K
Relative Volume:
0.58
Market Cap:
$413.78M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-9.2333
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
+10.10%
1M Performance:
+7.03%
6M Performance:
+14.84%
1Y Performance:
+138.79%
1-Day Range:
$6.865
$7.105
1-Week Range:
$6.18
$7.20
52-Week Range:
$2.71
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
6.93 | 413.78M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.80 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.64 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.07 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.15 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.51 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
ALDX stock touches 52-week high at $6.93 amid robust gains - Investing.com Australia
ALDX stock touches 52-week high at $6.93 amid robust gains By Investing.com - Investing.com South Africa
Tech Stocks Defying Market Volatility: Meet the Pioneers of Tomorrow’s Economy - DSA
High Growth Tech Stocks To Watch In The US March 2025 - Simply Wall St
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference - StockTitan
Aldeyra Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Q1 Earnings Estimate for ALDX Issued By HC Wainwright - Defense World
How to Take Advantage of moves in (ALDX) - Stock Traders Daily
Aldeyra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha
Chronic Cough Market Expected to rise, 2034 | Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., expected to drive market - Barchart
Chronic Cough Market Expected to rise, 2034 | Merck & Co, Kyorin - openPR
Aldeyra Therapeutics (NASDAQ:ALDX) Receives Buy Rating from HC Wainwright - Defense World
Aldeyra Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics Inc [ALDX] Insider Activity: An Update for Investors - Knox Daily
Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Aldeyra Therapeutics, Inc. SEC 10-K Report - TradingView
Best Stocks Under $10 • Charts Updated Daily - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Aldeyra Therapeutics, Inc. (ALDX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Thursday - Defense World
(ALDX) Trading Report - Stock Traders Daily
AlphaCentric Advisors LLC Acquires New Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
In-Depth Analysis Of The Chronic Plaque Psoriasis Market: Key Drivers, Trends, Growth Opportunities And - EIN News
Global Microtome Market to Exhibit Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire
Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA - openPR
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge - GlobeNewswire
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation ... - The Bakersfield Californian
ALDX stock touches 52-week high at $6.6 amid robust annual gains - MSN
Why Aldeyra Therapeutics Inc (NASDAQ: ALDX) Is A Great Stock Pick For Momentum Investors - Stocks Register
Dry Eye Disease Clinical Trial Pipeline | 45+ Companies Pioneering the Future of Treatment - EIN News
(ALDX) Proactive Strategies - Stock Traders Daily
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stake Raised by SG Americas Securities LLC - Defense World
Dry Eye Disease Market Poised for Major Advancements by 2034, Reveals DelveInsight - WICZ
Aldeyra Therapeutics Inc (ALDX) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Retinitis Pigmentosa Treatment Market Industry Growth - openPR
Exclusive Fireside Chat: Aldeyra CEO Reveals Company Strategy at Major Healthcare Conference - StockTitan
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Significant Growth in Short Interest - MarketBeat
How the (ALDX) price action is used to our Advantage - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Below 200-Day Moving AverageHere's What Happened - MarketBeat
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - News & Insights
Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - The Malaysian Reserve
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Crosses Below 200-Day Moving Average – Here’s Why - Defense World
ALDX (Aldeyra Therapeutics) Cash-to-Debt : 7.22 (As of Sep. 2024) - GuruFocus.com
Better Luck Next Year: US FDA CRLs May Be Rising, But Are Not The End Of The Story - insights.citeline.com
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in December - Defense World
Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Barclays PLC Acquires 48,313 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Jane Street Group LLC Has $128,000 Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):